This research project seeks to examine the patterns and costs of Pharmaceutical Benefits Scheme-subsidised opioid use, including extra-medical use, in the Australian population.
Treatment and Intervention
A recent randomised controlled trial found that Reduce your use was effective in assisting cannabis users to quit or cut down on their use.
Despite a high prevalence of drug and alcohol (AOD)-related morbidity among patients presenting to emergency departments, acute care settings and pre-admission clinics, previous research has found AOD-related morbidity is not commonly identified on admission.
The National Drug and Alcohol Research Centre (NDARC) have been invited to work with 5 remote NSW communities to retrospectively evaluate a suite of interventions aimed at prevention of drug and alcohol harms from 2012-2014.
This project will conduct the first randomised controlled trial of an internet delivered treatment for comorbid depression and binge drinking in young people aged 18-30 years, augmented with social networking support.
This project aims to describe patterns of AAS and PIEDs use; where people are sourcing them from and why; users' experience of harms; and users' utilisation of health services.
The Central Australian Youth Link Up Service (CAYLUS) supports community initiatives aimed at reducing the supply of, demand for, and harms associated with substance misuse among young people across Central Australia.
Substance use disorders (SUD) and post traumatic stress disorder (PTSD) are chronic, debilitating disorders that frequently co-occur (SUD+PTSD).
This project will provide crucial new data on the nature and trajectories of Pharmaceutical Opioid (PO) use through the study and follow-up of two very different and yet extremely important groups of pharmaceutical opioid users: those attending treatment services for PO dependence, and people who
Opioid agonist treatment is commonly initiated as a first-line treatment for individuals with pharmaceutical opioid dependence, even though much of the evidence base for the use of pharmacotherapy treatments in opioid dependence has been derived from studies conducted with primarily or exclusivel